Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug

A US appeals court ordered Jazz Pharmaceuticals on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the FDA ' s register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news